David A Hess
Overview
Explore the profile of David A Hess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel S, Badross M, Dhingra N, Moroney M, Casey J, Ali Hassan S, et al.
Ann Thorac Surg
. 2025 Jan;
PMID: 39889843
Background: Coronary artery bypass grafting (CABG) remains a cornerstone in the management of coronary artery disease (CAD). In nonurgent surgical revascularization cases, preoperative optimization of modifiable risk factors can improve...
2.
Serack F, Fennell K, Iliopoulos C, Walker J, Ronald J, Amsden B, et al.
J Biomed Mater Res A
. 2024 Sep;
113(1):e37800.
PMID: 39304971
Cell therapies harnessing the pro-vascular regenerative capacities of mesenchymal stromal cell (MSC) populations, including human adipose-derived stromal cells (hASCs), have generated considerable interest as an emerging treatment strategy for peripheral...
3.
Park B, Krishnaraj A, Teoh H, Bakbak E, Dennis F, Quan A, et al.
Am J Physiol Heart Circ Physiol
. 2024 Jun;
327(2):H370-H376.
PMID: 38874618
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline-recommended therapies for the management of type 2 diabetes (T2D), atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease....
4.
Krishnaraj A, Dennis F, Teoh H, Verma S, Hess D
Curr Opin Cardiol
. 2024 Jun;
39(5):444-450.
PMID: 38847610
Purpose Of Review: We aim to provide a comprehensive examination of the literature linking elevated rates of cardiovascular disease (CVD) in individuals of South Asian ethnicity with the severity of...
5.
Bakbak E, Krishnaraj A, Bhatt D, Quan A, Park B, Bakbak A, et al.
Med
. 2024 Mar;
5(7):718-734.e4.
PMID: 38552629
Background: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) showed that icosapent ethyl (IPE) reduced major adverse cardiovascular events by 25%. Since the underlying mechanisms for these benefits are...
6.
Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al.
Am J Physiol Heart Circ Physiol
. 2024 Mar;
326(5):H1159-H1176.
PMID: 38426865
Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for...
7.
Terenzi D, Bakbak E, Teoh H, Krishnaraj A, Puar P, Rotstein O, et al.
Cardiovasc Res
. 2024 Feb;
119(18):2858-2874.
PMID: 38367275
Ischaemic cardiovascular diseases, including peripheral and coronary artery disease, myocardial infarction, and stroke, remain major comorbidities for individuals with type 2 diabetes (T2D) and obesity. During cardiometabolic chronic disease (CMCD),...
8.
Krishnaraj A, Bakbak E, Teoh H, Pan Y, Firoz I, Pandey A, et al.
J Am Coll Cardiol
. 2024 Feb;
83(7):755-769.
PMID: 38355246
Background: South Asian individuals shoulder a disproportionate burden of cardiometabolic diseases. Objectives: The purpose of this study was to determine if vascular regenerative cell content varies significantly between South Asian...
9.
Bakbak E, Verma S, Krishnaraj A, Quan A, Wang C, Pan Y, et al.
Am J Physiol Heart Circ Physiol
. 2023 Sep;
325(5):H1210-H1222.
PMID: 37773589
Sodium glucose-cotransporter 2 (SGLT2) inhibitors have been reported to reduce cardiovascular events and heart failure in people with and without diabetes. These medications have been shown to counter regenerative cell...
10.
Bakbak E, Krishnaraj A, Park B, Verma S, Hess D
Curr Opin Cardiol
. 2023 Sep;
38(6):546-551.
PMID: 37668181
Purpose Of Review: This review will provide an overview of the recent literature linking the pathophysiology of cardiometabolic disease with the depletion and dysfunction of circulating vascular regenerative (VR) cell...